Effectiveness and safety of ezetimibe added to statin therapy in patients with primary dyslipidaemia not achieving the LDL-C treatment goal on statin monotherapy

Clinical Drug Investigation

Volumn 27, Issue 5, 2007, Pages 333-337

  González, Carlos A ^a   Rubio Guerra, Alberto F ^a,b   Pavía, Abel ^a   Redding, Francisco J ^a   Cervantes, José L ^a   Zacarías, José L ^a   Yza, Rubén ^a   Carranza, Jaime ^a   Fernández, Pedro ^a   Morales, Enrique ^a   Robles, Francisco J ^a   Leyva, José L ^a   Rodríguez, Leticia ^a  

^a Asociacion Mexicana para la Prevencion de la Aterosclerosis Y Sus Complicaciones AC (AMPAC)   (Mexico)

^b NONE   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY RISK; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POPULATION RESEARCH; PRIORITY JOURNAL;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 34248996994     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727050-00004     Document Type: Article

References (12)

1. Grundy SM, Cleeman JI, Bairey N, et al. For the coordinating committee of the National Cholesterol Education Program. Implications of recent trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39
2. Lara A, Rosas M, Pasteĺin G, et al. Hipercolesterolemia e hipertensíon arterial en Ḿexico: consolidacíon urbana actual con obesidad, diabetes y tabaquismo. Arch Cardiol Mex 2004; 74: 231-45
3. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of cholesterol levels. N Engl J Med 1998; 339: 1349-57
4. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomized placebo controlled trial. Heart protection study collaborative group. Lancet 2002; 360: 7-22
5. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double blind trial. Circulation 2003; 107: 2409-15
6. Sudohop T, L̈utjohann D, Modal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106: 1943-8
7. Catapano AL, Davidson MH, Ballantyne CM, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006; 22: 2041-53
8. Farnier M, Volpe M, Massad R, et al. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int J Cardiol 2005; 102: 327-32
9. Feldman T, Koren M, Insull W, et al. Treatment of high risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004; 93: 1481-6
10. Pearson TA, Denke MA, McBride PE, et al. A community-based randomized trial of ezetimibe added to statin therapy to attain NCEP ATPIII goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-on to Statin for Effectiveness (EASE) trial. Mayo Clin Proc 2005; 80: 587-95
11. Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin versus atorvastatin in patients with hypercholesterolemia: the VYtorin Versus Atorvastatin (VYVA) study. Am Heart J 2005; 149: 464-73
12. Goldberg RB, Guyton JR, Mazzone T, et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc 2006; 81: 1579-88